Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 13/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.48 |
| ▸ | CDK4 | P11802 | 5/20 | 0.48 |
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.48 |
| ▸ | CCND1 | P24385 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241780 | 0.93 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL10241774 | 0.85 | CDK9 (0.58) | CDK9CCNT1 | |
| SCHEMBL10241844 | 0.85 | CDK9 (0.58) | CDK9CCNT1 | |
| SCHEMBL10242731 | 0.81 | CDK9 (0.49) | CDK9PIP5K1CPIK3CA | |
| SCHEMBL10242725 | 0.81 | CDK9 (0.49) | CDK9PIP5K1CPIK3CA | |
| SCHEMBL1946411 | 0.77 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL1947145 | 0.77 | CDK9 (0.59) | CDK9CCNT1 | |
| SCHEMBL10241711 | 0.76 | CDK9 (0.60) | CDK9CCNT1 | |
| SCHEMBL10242056 | 0.76 | CDK9 (0.55) | CDK9CCNT1ABL1PIP5K1CPIK3CA | |
| SCHEMBL10244056 | 0.76 | CDK9 (0.59) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CDK9 6/4885CCNT1 80/4885CDK4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.